Angela H Brodie

Author PubWeight™ 6.23^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting abnormal DNA repair in therapy-resistant breast cancers.	Mol Cancer Res	2011	1.07
2	The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.	Breast Cancer Res Treat	2012	0.93
3	Challenges in the endocrine management of breast cancer.	Breast	2003	0.92
4	Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.	J Steroid Biochem Mol Biol	2012	0.88
5	HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.	Mol Cancer Ther	2013	0.85
6	Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.	Mol Cancer Ther	2013	0.81
7	Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.	Breast Cancer Res	2014	0.79